For inoperable NSCLC patients, we used sequencing of tissue samples to detect positive driver genes, through which treatment with targeted therapies was applied.4 Examples of these driver genes include EGFR mutation, ALK fusion, ROS1 fusion, BRAF V600E mutation/NTRK fusion and others.5-7 There has been an increasing evidence from clinical data that indicates the involvement of abnormal gene expressions and mutations in the occurrence and development of NSCLC. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.